Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISAV: dPCR to predict CML relapse after imatinib discontinuation
NCT01578213Phase 4Completed
- Sponsor
- University of Milano-Bicocca
- Start
- Nov 2011
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 4 trial of imatinib in chronic myeloid leukemia (CML), sponsored by University of Milano-Bicocca. Started Nov 2011; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01578213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578213.